 |
4 Products |  |
1 Disease | | 4 Products |
|
525 Trials |  |
2161 News |  |
| 12345678910111213...3738» |
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Review, Journal, Combination therapy, Monotherapy, Metastases: Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer: a narrative review. (Pubmed Central) - May 13, 2024
As for the combination of S-1 and immunotherapy, preliminary results of a phase II retrospective clinical trial demonstrated that the ORR was significantly better with S-1 sequential after immune checkpoint inhibitors (ICIs) than with S-1 alone. The findings indicate promising effectiveness and minimal toxicity with S-1 monotherapy and S-1 containing combined therapy in patients with advanced NSCLC to provide a potential treatment option for advanced NSCLC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma. (Pubmed Central) - May 11, 2024
Mechanistically, anlotinib affects CAF apoptosis and cell viability at least in part by inhibiting the AKT pathway. In conclusion, our study suggested that anlotinib could regulate the TME, inhibit the AKT pathway and promote CAF apoptosis, providing new insights into the antitumor effect of anlotinib and improving the efficacy of immunotherapy.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Multi-Omics Study on the Molecular Mechanism of Anlotinib in Regulating Tumor Metabolism. (Pubmed Central) - May 11, 2024
This regulation significantly influenced the metabolic levels of compounds such as sulfonic acids, cholesterol, inositol phosphate pyrophosphate, and palmitoyl-CoA in the tumor, thereby impacting tumor initiation and progression. This study provides potential metabolic biomarkers for anlotinib treatment in tumors.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Metastases: Combination anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report. (Pubmed Central) - May 10, 2024
Until the writing of the case draft, he had achieved another 11 months of PFS. The present case suggests that anlotinib plus toripalimab might be a potential effective treatment for advanced BTCs patients with high ECOG performance status.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma. (Pubmed Central) - May 8, 2024
Additionally, inhibition of OXPHOS biochemically negated METTL1's impact on anlotinib resistance. Overall, this study underscores the pivotal role of METTL1-mediated m7G tRNA modification in anlotinib resistance and lays the groundwork for novel therapeutic interventions to counteract resistance in OSCC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029). (Pubmed Central) - May 8, 2024
P2
This clinical trial was registered on www.clinicaltrials.gov (NCT03743129). Registration date: 6 September 2018.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, Metastases: Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial. (Pubmed Central) - May 6, 2024
Registration date: 6 September 2018. Anlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review. (Pubmed Central) - May 1, 2024
MGTs occurring in the bladder are clinically rare and refractory. The case presented here highlights the importance of multidisciplinary diagnosis and treatment, providing evidence that radiotherapy and antiangiogenic therapy may play an important role in unresectable bladder MGT.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Retrospective data, Journal, Combination therapy, Metastases: Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer. (Pubmed Central) - Apr 28, 2024
No difference was seen in the occurrence of adverse reactions between 2 groups (P=0.35). In treating advanced NSCLC patients, anlotinib combined with docetaxel can promote efficacy to a certain extent, effectively regulate the level of serum tumor markers, promote the quality of life of patients, and will not significantly affect clinical safety.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, IO biomarker: Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway. (Pubmed Central) - Apr 28, 2024
In treating advanced NSCLC patients, anlotinib combined with docetaxel can promote efficacy to a certain extent, effectively regulate the level of serum tumor markers, promote the quality of life of patients, and will not significantly affect clinical safety. Anlotiniband 5-fluorouracil?+?cisplatin (5-FU?+?DDP) was administered separately to human esophageal cancer TE- 1 cells tumor xenograft mouse models every 3
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, Combination therapy: The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study. (Pubmed Central) - Apr 27, 2024
pCR was higher than what has been reported in previous clinical studies of chemotherapy alone. This study provides additional rationale for using anlotinib plus docetaxel-epirubicin-based chemotherapy regimen in patients with early-stage TNBCs.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer. (Pubmed Central) - Apr 27, 2024
This study provides additional rationale for using anlotinib plus docetaxel-epirubicin-based chemotherapy regimen in patients with early-stage TNBCs. Anlotinib combined with etoposide emerged effective for the treatment of PROC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Brain radiotherapy and anlotinib control primary cardiac angiosarcoma with metastases: A case report. (Pubmed Central) - Apr 26, 2024
Anlotinib combined with etoposide emerged effective for the treatment of PROC. The treatment for metastatic PCA needs an in-depth exploration.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study. (Pubmed Central) - Apr 26, 2024
This study first reported that anlotinib combined with Stupp regimen is a safe and feasible regimen for newly diagnosed patients with H3K27M-DMG. Further, anlotinib showed significant efficacy for H3K27M-DMG located in the infratentorial region.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway. (Pubmed Central) - Apr 25, 2024
Anlotinib effectively inhibits proliferation and induces apoptosis in MCL both in vitro and in vivo. This inhibition is likely linked to suppressing phosphorylation in the PI3K/Akt/mTOR pathway.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Metastases: Anlotinib in Chinese patients aged ?70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial. (Pubmed Central) - Apr 23, 2024
The most common grade ?3 TRAEs were hypertension (4/40; 10.0%), hand-foot syndrome (3/40; 7.5%), and proteinuria (2/40; 5.0%). Anlotinib treatment was feasible and safe in Chinese elderly patients with advanced non-squamous NSCLC who did not receive any systemic chemotherapy.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data. (Pubmed Central) - Apr 23, 2024
Anlotinib monotherapy or in combination with radionuclide therapies shows promising efficacy and safety for the treatment of LA/M PCC and PGL. Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required.
- | Tevimbra (tislelizumab) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC (clinicaltrials.gov) - Apr 23, 2024
P2, N=20, Not yet recruiting, Sponsor: Ji Yongling
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial primary completion date, Metastases: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) - Apr 23, 2024
P2, N=30, Completed, Sponsor: Shanghai Changzheng Hospital
Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required. Recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2023
- | Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial completion date, Trial primary completion date: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (clinicaltrials.gov) - Apr 22, 2024
P1, N=33, Completed, Sponsor: Shanghai Chest Hospital
Recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2023 Recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Jul 2023
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: IL-1? facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation. (Pubmed Central) - Apr 22, 2024
Overall, the current study demonstrates novel evidence that the autocrine IL-1? favors endogenous anti-oxidative process and confers therapeutic resistance to nutrition-starvation in OSCCs.
- || lobaplatin (D19466) / AEterna Zentaris, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, BRCA Biomarker: Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial. (Pubmed Central) - Apr 19, 2024
favors endogenous anti-oxidative process and confers therapeutic resistance to nutrition-starvation in OSCCs. Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12
- | Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date: Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer (clinicaltrials.gov) - Apr 18, 2024
P2, N=35, Recruiting, Sponsor: Zhongnan Hospital
Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025
- || Opdivo (nivolumab) / Ono Pharma, BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Combination therapy: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=56, Active, not recruiting, Sponsor: Sarcoma Oncology Research Center, LLC
Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov) - Apr 17, 2024
P2, N=27, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Feb 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
- || Retrospective data, Review, Journal, Metastases: Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis. (Pubmed Central) - Apr 16, 2024
Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.
- | Retrospective data, Journal, Checkpoint inhibition: Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis. (Pubmed Central) - Apr 16, 2024
Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma. PD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-na
- | sunvozertinib (DZD9008) / Dizal Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: WUKONG-32-RW: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (clinicaltrials.gov) - Apr 9, 2024
P2, N=100, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Metastases: A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 8, 2024
P2/3, N=266, Recruiting, Sponsor: Army Medical Center of PLA
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 7, 2024
P2, N=64, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, IO biomarker: Galectin-1 overexpression induces normal fibroblasts translate into cancer-associated fibroblasts and attenuates the sensitivity of anlotinib in lung cancer. (Pubmed Central) - Apr 5, 2024
PD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-na Tumor volume and weight in CMs treated mice were increased, and the sensitivity of anlotinib in co-cultured
- | sunvozertinib (DZD9008) / Dizal Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: WUKONG-32: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (clinicaltrials.gov) - Apr 4, 2024
P2, N=52, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
- ||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion date, Trial termination, Metastases: AK105-301: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 4, 2024
P3, N=164, Terminated, Sponsor: Akeso
Tumor volume and weight in CMs treated mice were increased, and the sensitivity of anlotinib in co-cultured Trial completion date: Jun 2024 --> Dec 2023 | Active, not recruiting --> Terminated; corporate strategy adjustment
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Metastases: The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer. (Pubmed Central) - Apr 4, 2024
Our study indicated that, when combined with anlotinib following gradual progression on EGFR-TKIs, it was more efficacious for EGFR-mutant NSCLC patients than EGFR-TKI monotherapy. And the toxicity was clinically manageable.
- || Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion: AK105-203: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 3, 2024
P2, N=31, Completed, Sponsor: Akeso
And the toxicity was clinically manageable. Active, not recruiting --> Completed
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 2, 2024
P2, N=28, Completed, Sponsor: Akeso
Active, not recruiting --> Completed Recruiting --> Completed | N=90 --> 28 | Trial completion date: Jun 2023 --> Dec 2023
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 2, 2024
P2, N=33, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Tumor cell: Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma. (Pubmed Central) - Apr 1, 2024
Moreover, it can play an anti-tumor role through blocking cell cycle G2/M and promoting apoptosis, which may be related to the decrease of HIF-1a expression. Our study would provide a potential treatment method for patients with hypopharyngeal cancer.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence, Real-world, Metastases: A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer. (Pubmed Central) - Mar 30, 2024
Our study would provide a potential treatment method for patients with hypopharyngeal cancer. Our data confirms the effectiveness of Gemcitabine plus Anlotinib and anti-PD1 as a well-tolerated regimen in the second-line treatment of APC and extends available data on its use as a second-line treatment option when compared with FOLFIRINOX.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, metatinib tromethamine (BMS-794833) / Simcere
Journal: BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. (Pubmed Central) - Mar 27, 2024
Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET)...More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo. Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Journal: CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. (Pubmed Central) - Mar 26, 2024
P2
Patient-derived organoids and xenograft models are employed to validate the sensitivity to anlotinib. Furthermore, our preliminary Phase II clinical study, involving advanced CRC patients treated with anlotinib, confirmed circHAS2 as a potential sensitivity marker.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. (Pubmed Central) - Mar 26, 2024
The combination of anlotinib and PD-1 inhibitors demonstrated a promising clinical effect compared to fluoropyrimidine-based chemotherapy in the second-line treatment of refractory advanced BTCs. Liver metastases and CEA levels may serve as predictive factors for identifying patients who may benefit from AP therapy.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, Metastases: Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer (clinicaltrials.gov) - Mar 26, 2024
P1, N=42, Not yet recruiting, Sponsor: Fudan University
- | Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure (clinicaltrials.gov) - Mar 25, 2024
P2, N=30, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- || Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. (Pubmed Central) - Mar 22, 2024
P2
The findings support further randomized controlled trials of this combination regimen for ED-SCLC. Henan Province Health and Youth Subject Leader Training Project, Henan Health Science and Technology Innovation Talents, ZHONGYUAN QIANREN JIHUA, Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer, Tumor Research Fund of Anti-Angiogenesis Targeted Therapy of China Anti-Cancer Association.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Surgery: Surgery combined with anlotinib for local control of patients with resectable extremity desmoid fibromatosis: a retrospective study. (Pubmed Central) - Mar 22, 2024
The 3-year recurrence-free survival (RFS) of the surgery alone cohort and the surgery plus anlotinib cohort were 37.7% and 72.6%, respectively, and the difference was statistically significant (p = 0.022). Surgery combined with anlotinib appears to be effective in controlling local recurrence in patients with resectable DF of the extremities, and the side effects were acceptable.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: FAM83D acts as an oncogene by regulating cell cycle progression via multiple pathways in synovial sarcoma: a potential novel downstream target oncogene of anlotinib. (Pubmed Central) - Mar 21, 2024
Surgery combined with anlotinib appears to be effective in controlling local recurrence in patients with resectable DF of the extremities, and the side effects were acceptable. This experimental study identified FAM83D as a critical regulator that contributes to the proliferation and progression of SS, suggesting that FAM83D-regulated signaling pathway may serve as a prospective target in SS management.
- | AL2846 / Advenchen, Sino Biopharm
Enrollment change, Trial completion date, Trial termination: A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov) - Mar 21, 2024
P1/2, N=22, Terminated, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This experimental study identified FAM83D as a critical regulator that contributes to the proliferation and progression of SS, suggesting that FAM83D-regulated signaling pathway may serve as a prospective target in SS management. N=192 --> 22 | Trial completion date: Dec 2024 --> Feb 2024 | Recruiting --> Terminated; sponsor adjusts its research and development strategy
- | Tagrisso (osimertinib) / AstraZeneca, Conmana (icotinib) / Betta Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Journal: Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. (Pubmed Central) - Mar 18, 2024
Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mutation was an independent risk indicator of shorter OS following third-line treatments. Comprehending the tumor evolution in NSCLC is advantageous for assessing the efficacy and prognosis at each stage of treatment, providing valuable insights to guide personalized treatment decisions for patients.
- || Retrospective data, Review, Real-world evidence, Real-world, Metastases: Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies. (Pubmed Central) - Mar 16, 2024
In real-world clinical practice, ATC patients could benefit from TKI therapy. In future studies, more basic experiments and clinical explorations are needed to enhance the effects of TKIs in the treatment of patients with ATC.